Ionis' (IONS) "Data for Eplontersen are Highly Likely to be Positive on Efficacy" - Stifel Reiterates Hold Ahead of Phase 3 Readout with $33 Price Target
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
